Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor Recurrence

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Low-grade non-muscle-invasive urothelial cancer frequently recurs after excision by transurethral resection of bladder tumor (TURBT).

Related collections

Author and article information

Journal

Title: JAMA

Abbreviated Title: JAMA

Publisher: American Medical Association (AMA)

ISSN (Print): 0098-7484

Publication date Created: May 08 2018

Publication date (Print): May 08 2018

Volume: 319

Issue: 18

Page: 1880

Affiliations

[1 ]University of Rochester, Rochester, New York

[2 ]SWOG Statistical Center, Seattle, Washington

[3 ]Fred Hutchinson Cancer Research Center, Seattle, Washington

[4 ]Baylor College of Medicine, Houston, Texas

[5 ]Oregon Health & Science University, Portland

[6 ]Beaumont Health, Royal Oak, Michigan

[7 ]University of California Davis, Sacramento

[8 ]University of Texas–San Antonio, San Antonio

[9 ]University of Michigan, Ann Arbor

[10 ]University of Oklahoma, Oklahoma City

[11 ]Madigan Army Medical Center, Tacoma, Washington

[12 ]Urology Center of Colorado, Denver

[13 ]University of Kansas Cancer Center, Kansas City

[14 ]University of Colorado, Aurora

[15 ]Comprehensive Cancer Centers of Nevada, Las Vegas

[16 ]CHRISTUS Santa Rosa Medical Center, San Antonio, Texas

Article

DOI: 10.1001/jama.2018.4657

PMC ID: 6583489

PubMed ID: 29801011

SO-VID: a207f8d6-7124-43ee-a7a0-3b58b7133fc2

History

Data availability:

Comments

Comment on this article

scite_

Cited by 69

See all cited by

- Version 1
- Version 1

Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor Recurrence : SWOG S0337 Randomized Clinical Trial

Read this article at